Who owns Dyne Therapeutics, Inc. (DYN)? Elite investor 13F holders

2 tracked elite investors reported holding Dyne Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCDYNEGY INCSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Renaissance Technologies LLCDYNE THERAPEUTICS INCSHARE2026-06-302026-08-13 00:00:008008304.00 USD360572.000000SharesbuyOriginal filing
Tudor InvestmentDYNE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
D.E. ShawDYNE THERAPEUTICS INCSHARE2026-06-302026-08-14 00:00:001336176.00 USD60161.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown